The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
Researchers assessed changes in the estimated glomerular filtration rate among patients with gout with moderate renal impairment, using a treat-to-target approach for gout.
Chronic kidney disease (CKD) is a commonly diagnosed condition, affecting approximately 30 million adults in the United States.1 CKD refers to a diverse group of pathologies that result in kidney function decline for at least 3 months.2,3 Kidney disease etiologies are generally classified into 3 categories: prerenal, intrinsic renal, and postrenal. Prerenal disease is marked…
ESKD risk highest for women with preterm preeclampsia and/or preeclampsia in two pregnancies.
A recently published report describes the case of a 62-year-old patient who experienced rare but serious central nervous system (CNS) side effects following the initiation of gabapentin therapy.
A recently published report describes the case of a 62-year-old patient who experienced rare but serious central nervous system (CNS) side effects following the initiation of gabapentin therapy.
Also do not correlate well with reperfusion biopsies, not linked to transplant outcomes
Patients who lose 10% or more of their body weight from the time of their listing on a transplant waiting list are at higher risk of death following deceased-donor kidney transplantation.
Preemptively listed recipients have about four fewer years of pretransplant dialysis
